MTCH1 and cardiomyopathy: Doxorubicin‐induced cardiomyopathy involves mitochondrial energy metabolism dysfunction, exacerbated by cardiomyocyte‐specific Slc25a49 deficiency via oxidative phosphorylation (OXPHOS) suppression and glycolysis activation.